InGeneron
Business Services · Germany · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Sonnenstr. 24-26, Munich, Bavaria, 80331...Phone Number
+49 891499031927Website
www.ingeneron.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About InGeneron
InGeneron GmbH is a clinical-stage biotechnology company developing novel, safe, and evidence-based cell therapies. They are setting new therapeutic standards by enabling minimally invasive treatments that unlock the healing potential of each patient’s regenerative cells processed at the point of care for same-day treatment. InGeneron GmbH currently focuses on helping patients impacted by orthopedic conditions and is conducting several clinical trials to validate their technology as a disease-modifying treatment.Explore more
InGeneron Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is InGeneron your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once InGeneron has new funding data
Check if InGeneron has recently received funding, and reach out quickly before it becomes old news!
Click to see if InGeneron had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when InGeneron launches new products
Check out if InGeneron is spiking on competitors!
InGeneron, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at InGeneron
Earning: See what the market has to say on InGeneron recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined InGeneron as Masked Content
Find 2 more new buyers
Compare Similar Companies to InGeneron
Compare insights from companies similar to InGeneron, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
InGeneron is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
InGeneron is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about InGeneron.
InGeneron financials insights
Gather financial insights about InGeneron, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$4.5M
2016
Multiple Rounds
$8.8M
2017
Series D
$20M
2020
Debt
$150K
InGeneron Tech Stack
A closer look at the technologies used by InGeneron
See more technologies
Most Recent Scoops
Funding
InGeneron has received an SBA PPP loan for $150,000-350,000 from Zions Bank, supporting the retention of 20 jobs.
Funding
Funding
Funding
, a biotechnology company, recently secured $3.5 million in funding as part of a round targeted at $23 million.
Funding
Funding
InGeneron News & Media
InGeneron Reports Positive Long-Term Results for its Cell Therapy in Partial-Thickness Rotator Cuff Tears
HOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a clinical-stage biotechnology company, today announced positive clinical trial data demonstrating long-term safety and efficacy of InGeneron’s cell therapy for treating partial-thickness rotator cuff tears. The results of InGeneron's randomized, controlled study, which followed patients for 3.4 years after treatment, were published under the title "Management of partial-thickness rotator cuff tears with autologous adipose-derived regenerative cells isInGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial
HOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a clinical stage biotechnology company, announces the publication of a Phase III 480-patient clinical trial sponsored by Emory University (Atlanta, GA, USA). Published in the Journal Nature Medicine on November 2nd, 2023, the study, entitled “Cell based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial”, investigated the efficacy of InGeneron’s regenerative cell therapy in comparison to two other orthobiologicNew Study Reports Broad Applicability of InGeneron’s Regenerative Cell Therapy System Across Patient Groups
HOUSTON--(BUSINESS WIRE)--InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a newly released study, titled “The composition of adipose-derived regenerative cells isolated from lipoaspirate using a novel point of care system does not depend on the subject's individual age, sex, body mass index and ethnicity”, published in the Journal Cells on December 21, 2022. The study, which characterized the composition of regenerative cells isolated from adipose tissue ofInGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics
HOUSTON--(BUSINESS WIRE)--InGeneron announced the publication of a succinct scientific review of regenerative cell therapy to treat orthopedic indications.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding InGeneron
Sign Up For FreeTo access detailed company insights
InGeneron GmbH is a clinical-stage biotechnology company developing novel, safe, and evidence-based cell therapies. They are setting new therapeutic standards by enabling minimally invasive treatments that unlock the healing potential of each patient’s regenerative cells processed at the point of care for same-day treatment. InGeneron GmbH currentl... Read More
